2022 | Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
| CANCER DISCOVERY |
2022 | The Essentials of Multiomics
| ONCOLOGIST |
2022 | International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1)
| ANNALS OF GASTROENTEROLOGICAL SURGERY |
2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
2022 | Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials | JOURNAL OF CLINICAL ONCOLOGY |
2022 | Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial | JOURNAL OF CLINICAL ONCOLOGY |
2022 | Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 | JOURNAL OF CLINICAL ONCOLOGY |
2021 | Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer | CELLULAR ONCOLOGY |
2021 | Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer
| CANCER MEDICINE |
2021 | Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
| ONCOLOGIST |
2021 | Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
| ESMO OPEN |
2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
2021 | Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2021 | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | JOURNAL OF CLINICAL ONCOLOGY |
2021 | SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence
| GASTRIC CANCER |
2021 | "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy | CANCER RESEARCH |
2021 | Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population
| GUT |
2021 | Detection of asymptomatic recurrence improves survival of gastric cancer patients
| CANCER MEDICINE |
2021 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
2021 | Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea
| CANCER RESEARCH AND TREATMENT |
2021 | Stable Symptom Clusters and Evolving Symptom Networks in Relation to Chemotherapy Cycles | JOURNAL OF PAIN AND SYMPTOM MANAGEMENT |
2021 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis | EUROPEAN JOURNAL OF CANCER |
2021 | Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
| FRONTIERS IN PHARMACOLOGY |
2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
2020 | Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
| Genomics & Informatics |
2020 | Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma | NATURE GENETICS |
2020 | Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma
| DIAGNOSTICS |
2020 | Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
| FRONTIERS IN ONCOLOGY |
2020 | Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
| MOLECULAR THERAPY-ONCOLYTICS |
2020 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
| JOURNAL OF CLINICAL ONCOLOGY |
2020 | Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells
| YONSEI MEDICAL JOURNAL |
2020 | Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial | SUPPORTIVE CARE IN CANCER |
2020 | Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients | SUPPORTIVE CARE IN CANCER |
2019 | Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
| EUROPEAN UROLOGY ONCOLOGY |
2019 | Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
| FUTURE ONCOLOGY |
2019 | Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
2019 | Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy | SUPPORTIVE CARE IN CANCER |
2019 | A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer | GASTRIC CANCER |
2019 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
| BMC CANCER |
2019 | Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma
| YONSEI MEDICAL JOURNAL |
2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
2019 | Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer | GASTRIC CANCER |
2019 | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
| Journal for Immunotherapy of Cancer |
2019 | Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
| CANCER RESEARCH AND TREATMENT |
2019 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
| CANCER RESEARCH AND TREATMENT |
2019 | Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
| Cancer Research and Treatment |
2019 | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma | Oncology |
2019 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
| Cancer Research and Treatment |
2019 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
| Cancer Research and Treatment |